Miller Thomas F.
Miller Thomas F., CEO, reported a transaction classified as grant at Iambic Therapeutics, Inc. involving 793200.000000 shares for an estimated $0.00. Reported holdings after the transaction were 793200.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 14, 2026
- Filing date
- Oct 16, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
IAM price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0002034921-26-000007 Employee Stock Option (right to buy)
- Transaction date
- Oct 14, 2026 Filed Oct 16, 2026, 08:07 PM · 2d delay
- Shares
- 793,200 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 793,200 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Executive Officer
- F1
The reported shares are represented by restricted stock units, or RSUs, which vest as follows: 25% of the RSUs vest on September 10, 2027 and the remaining RSUs vest in twelve equal quarterly installm…
- F2
Twenty-five percent of the shares subject to the option vest on October 14, 2027 and 1/48th of the shares vest monthly thereafter.
0 other transactions
0 recent txs